Rossari Biotech Q1 FY27 Results (NSE: ROSSARI)
Signal: Margin pressure
The read
Q1FY27 revenue grew a robust 28.2% YoY to ₹6,972 Mn, yet OPM contracted for the 5th consecutive quarter to 11.1% (-140bps YoY) as raw material costs rose and finance costs surged 91.6% YoY. The margin erosion has become structural — revenue growth is not translating to profit growth; PAT barely rose +4.5%. With industry P/E of 31x vs company 21.7x, valuation may already price in this trend, but the trajectory needs a catalyst to reverse compression.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹697.2 Cr | 28.2% | 1.8% |
| EBIT | ₹47.22 Cr | 3.6% | |
| Net profit | ₹35.1 Cr | 4.5% | |
| EPS | ₹6.34 | 4.1% | |
| EBIT margin | 11.1% |
P&L walk
Revenue grew 28.2% YoY driven by volume/mix, but OPM compressed 140bps to 11.1% as raw material costs rose 120bps as % of revenue and finance costs increased 40bps — 5th straight quarter of margin contraction.
Key positives
- Revenue grew 28.2% YoY, accelerating from prior quarters and showing strong demand momentum.
- Employee cost as % of revenue declined 80bps YoY, indicating some operating efficiency.
- Other expenses as % of revenue fell 80bps YoY, showing fixed cost control.
Key concerns
- OPM contracted 140bps YoY to 11.1% — 5th consecutive quarter of margin compression.
- Finance costs nearly doubled YoY (+91.6%), outpacing revenue growth and indicating rising leverage or higher interest rates.
- PAT growth (+4.5%) severely lagged revenue growth (+28.2%) as margin compression absorbed operating leverage.
Research and educational content only. Not investment advice.